"...for the pre-exposure prophylaxis of coronavirus disease 2019...Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2..."

https://www.fda.gov/media/154701/download

 Paxlovid?

 The trial, "...enrolled non-hospitalized adults aged 18 and older with confirmed COVID-19 who are at increased risk of progressing to severe illness...PAXLOVID can be used to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease."

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel

 Molnupiravir?

 Not authorized, "...for initiation of treatment in patients hospitalized due to COVID-19..."

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain

 Sotrovimab?

 "Sotrovimab is not authorized for use in patients:
 o who are hospitalized due to COVID-19, OR
 o who require oxygen therapy due to COVID-19, OR
 o who require an increase in baseline oxygen flow rate due to COVID-19"

https://www.fda.gov/media/149534/download

 Lilly mAb cocktail?

 "Treatment with bamlanivimab and etesevimab has not been studied in patients hospitalized due to COVID-19."

https://www.covid19.lilly.com/bam-ete/hcp

 Besides, the FDA has shelved their product.

 REGEN-COV?

 "...not authorized for use in patients who are hospitalized due to COVID-19, OR who require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen..."

https://www.regencov.com/

 The FDA has also shelved Regen-Cov.

https://cbsaustin.com/news/local/two-of-three-monoclonal-antibody-covid-19-treatments-not-effective-against-omicron

  who have a baseline CRP of <150mg/L (which represented about 80 % of our LIVE-AIR trial patients, and should represent about 400 of the ACTIV-5 NIH trial patients). Toci is suggested to treat hospitalized patients with CRP> 175mg/L, as I recall. That is not a patient population that HGEN wants to use their limited product to treat.

"코로나바이러스 질병 2019의 감염 전 예방책을 위해...현재 SARS-CoV-2에 감염되지 않았으며 최근 SARSCoV-2에 감염된 개인에 대한 알려진 노출이 없는 사람들이다.

https://www.fda.gov/media/154701/download

팍스로비드?

이 재판은 18세 이상의 비입원 성인을 중증으로 진행될 위험이 높은 COVID-19 확진자로 등록했다.PAXLOVID는 보충 산소가 필요하지 않고 중증 질환으로 진행될 위험이 높은 COVID 성인을 치료하는 데 사용할 수 있다."

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel

몰누피라비르?

"... COVID-19로 인해 입원한 환자의 치료를 시작하기 위해 승인되지 않았습니다."

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain

소트로비맙?

"소트로비맙은 환자에게 사용할 수 없습니다.
o COVID-19로 인해 병원에 입원한 사람들
o COVID-19로 인해 산소 치료가 필요한 경우
o COVID-19로 인해 기준 산소 유량의 증가가 필요한 사람"

https://www.fda.gov/media/149534/download

릴리 mAb 칵테일?

"밤라니비맙과 에테스비맙을 이용한 치료는 COVID-19로 인해 입원한 환자들에게서 연구되지 않았습니다."

https://www.covid19.lilly.com/bam-ete/hcp

게다가, FDA는 그들의 제품을 보류했습니다.

리젠-코브?

"...COVID-19로 인해 입원한 환자, COVID-19로 인해 산소 치료가 필요한 환자, 기준 산소 증가가 필요한 환자에게는 사용이 허가되지 않았습니다.."

https://www.regencov.com/

FDA도 Regen-Cov를 보류했다.

https://cbsaustin.com/news/local/two-of-three-monoclonal-antibody-covid-19-treatments-not-effective-against-omicron 

기준 CRP는 150mg/L(LIVE-AIR 시험 환자의 약 80%를 대표하며 ACTIVATE-5 NIH 시험 환자 중 약 400명을 대표해야 함)이다. 제가 기억하기로는, Toci는 CRP> 175mg/L의 입원 환자를 치료하는 것이 좋습니다. HGEN이 제한된 제품을 사용하여 치료하고자 하는 환자 집단은 아닙니다.